Hamzeh Rezaei
Harnessing CRISPR/Cas9 technology in cardiovascular disease
Rezaei, Hamzeh; khadempar, Saedeh; Farahani, Najmeh; Hosseingholi, Elaheh Zadeh; hayat, Seyed Mohammad Gheibi; Sathyapalan, Thozhukat; Sahebkar, Amir hossein
Authors
Saedeh khadempar
Najmeh Farahani
Elaheh Zadeh Hosseingholi
Seyed Mohammad Gheibi hayat
Professor Thozhukat Sathyapalan T.Sathyapalan@hull.ac.uk
Professor of Diabetes, Endocrinology and Metabolism
Amir hossein Sahebkar
Abstract
The CRISPR/Cas9 system is a precisely targeted bacterial defense system, used to control invading viruses. This technology has many potential applications including genetic changes in somatic and germ cells and the creation of knockout animals. Compared to other genome editing techniques such as zinc-finger nucleases and transcription activator-like effector nucleases (TALENS), the CRISPR/Cas9 system is much easier and more efficient. Most importantly, the multifunctional capacity of this technology allows simultaneous editing of several genes. The CRISPR/Cas9 system also potentially has the ability to prevent and treat human diseases. The present article addresses some key points related to the use of the CRISPR/Cas9 system as a powerful tool in cardiovascular research and as a new strategy for the treatment of cardiovascular disease (CVD).
Citation
Rezaei, H., khadempar, S., Farahani, N., Hosseingholi, E. Z., hayat, S. M. G., Sathyapalan, T., & Sahebkar, A. H. (2020). Harnessing CRISPR/Cas9 technology in cardiovascular disease. Trends in Cardiovascular Medicine, 30(2), 93-101. https://doi.org/10.1016/j.tcm.2019.03.005
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 14, 2019 |
Online Publication Date | Mar 26, 2019 |
Publication Date | Feb 1, 2020 |
Deposit Date | Mar 30, 2019 |
Publicly Available Date | Mar 27, 2020 |
Journal | Trends in Cardiovascular Medicine |
Print ISSN | 1050-1738 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 30 |
Issue | 2 |
Pages | 93-101 |
DOI | https://doi.org/10.1016/j.tcm.2019.03.005 |
Keywords | CRISPR/Cas9; Genome editing; Cardiovascular disease |
Public URL | https://hull-repository.worktribe.com/output/1479289 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S1050173819300428?via%3Dihub |
Additional Information | This is the accepted manuscript of an article published in Trends in cardiovascular medicine, 2019. The version of record is available at the DOI link in this record. |
Contract Date | Apr 1, 2019 |
Files
Article
(960 Kb)
PDF
Licence
https://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
Copyright Statement
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
Molecular Aspects of Cardiovascular Risk Factors
(2024)
Journal Article
Effect of Hypoglycemia and Rebound Hyperglycemia on Proteomic Cardiovascular Risk Biomarkers
(2024)
Journal Article
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search